|
SELECTED ARTICLES FROM THE RECENT LITERATURE 2006
11/1/06
Giant cell arteritis and polymyalgia rheumatica
Summary
Background - Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are often associated disorders occurring predominantly in the elderly population. There appears to be an increasing frequency of GCA and PMR in the USA with increasing numbers of individuals living to advanced ages.
Findings - Some clinical aspects of GCA and PMR were reviewed by Gonzalez-Gay et al of Lugo, Spain. GCA is manifested mainly by its involvement of cranial arteritis, particularly the external carotid branches. Jaw claudication, head pain, local tenderness, particularly over the temporal arteries, and sometimes visual loss due to retinal artery occlusion are the main symptoms of GCA.
PMR is characterized clinically by aching pain and morning stiffness involving the neck, shoulder and hip girdles.
In both GCA and PMR there is prominent increase in the ESR and C-reactive protein levels. A temporal artery biopsy (sometimes needed bilaterally) is the most definitive diagnostic test in GCA, particularly when there is tenderness in that temporal region. There is no single diagnostic test for PMR.
Corticosteroids (CS) are still the major treatment in both PMR and GCA with prompt symptomatic response of PMR to about 20 mg prednisone/day. Higher initial CS doses (40-60 mg/day) are often needed to control GCA. The dose of CS are reduced gradually when the symptoms abate and the ESR decreases towards normal However, relapses are common when the CS treatment is withdrawn completely, necessitating resumption and then long-term treatment with low dosage CS. Therefore, other agents including some newer biologic agents, are tried as additive therapy as a CS dose sparing approach.
Reference
Drugs Aging 2006;23:627-49
Editor's Comments
An appropriate diagnosis and treatment of GCA/PMR can markedly reduce symptoms which considerably affect quality of life. Such treatment may also prevent loss of vision due to retinal artery involvement. However, daily CS treatment is frequently needed (alternate day therapy is ineffective). Thus, added treatment with a bisphosphonate and calcium/Vit D is needed. It is still unclear whether infliximab or rituximab monoclonal antibody treatment will be CS-sparing in these disorders.
|